갈색홍채에서 브리모니딘 0.15%의 야간 항산동 효과 = The Antimydriatic Effect of Brimonidine 0.15% on the Dark-adapted Pupil in Dark Brown Irides

다국어 초록 (Multilingual Abstract)

Purpose: To analyze the effect of the daily use of brimonidine tartrate 0.15% on the dark-adapted pupil diameter in dark brown irides. Methods: Twenty-five healthy volunteers administered brimonidine tartrate 0.15% to their right eyes once daily for 3 weeks. Infrared digital photographs of the pupil were taken before administration and 1 hour and 4 hours after administration after dark adaptation (at <0.1 lux ambient illumination for 5 minutes). The diameters of both pupils were measured on the first day, on administration days 7 and 21, and on washout day 7. Results: Four hours after the first administration, pupils showed a decrease of 0.95±0.74 mm, 1.03±0.94 mm, 0.61±0.85 mm on the first day, administration day 7, and administration day 21, respectively (p<0.01), compared with baseline data. The anti-mydriatic effect of brimonidine was sustained for 3 weeks, but the proportions of the eyes showing a reduction in pupil diameter by 0.5 mm or more were 84%, 76%, 68%, and 52% at 4 hours on the first day, administration days 7 and 21, and washout day 7, respectively. Conclusions: The anti-mydriatic effect of the daily use of brimonidine 0.15% on dark brown irides in a scotopic condition is maintained during the instillation period but has a tendency to fade over time. This point should be considered when using this compound as a miotic agent. J Korean Ophthalmol Soc 2008;49(10):1649-1657

참고문헌 (Reference)

1 Patil PM, "Unequal accumulation of adrenergic drugs by pigmented and nonpigmented iris" 78 : 470-477, 1974

2 Bergamin O, "The influence of iris color on the pupillary light reflex" 236 : 567-570, 1998

3 Brown SM, "The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter" 138 : 149-151, 2004

4 Brogliatti B, "Pupillographic, tonographic and refractive parameter changes after topical instillation of Brimonidine tartrate 0.2% in healthy subjects" 227 : 34-35, 1998

5 Douglas DK, "Pupillary size and responsiveness" 98 : 1030-1035, 1991

6 Morales J, "Ocular effects of apraclonidine in Horner syndrome" 118 : 951-954, 2000

7 Abdulrazik M, "Non-systemic delivery of topical brimonidine to the brain: a neuro-ocular tissue distribution study" 14 : 670-679, 2006

8 Thorden JE, "Miotic effect of brimonidine tartrate 0.15% ophthalmic solution in normal eyes" 30 : 1702-1706, 2004

9 Faulkner W, "Miotic effect of alphagan P" 29 : 423-, 2003

10 Lackner B, "Glare and halo phenomena after laser in situ keratomileusis" 29 : 444-450, 2003

11 Schmidt GW, "Evaluation of the relationship between ablation diameter, pupil size, and visual function with vision-specific quality-of-life measures after laser in situ keratomileusis" 125 : 1037-1042, 2007

12 Marchini G, "Effects of 0.2% brimonidine on ocular anterior structures" 15 : 337-344, 1999

13 Martinez CE, "Effect of pupillary dilation on corneal optical aberrations after photorefractive keratectomy" 116 : 1053-1062, 1998

14 McDonald JE II, "Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions" 27 : 560-564, 2001

15 Kesler A, "Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size" 30 : 1707-1710, 2004

16 Brown SM, "Effect of brimonidine on pupil diameter" 31 : 1686-1687, 2005

17 O`Brart DP, "Disturbance in night vision after excimer laser photorefractive keratectomy" 8 : 46-51, 1994

18 Brown SM, "Day to day variability of the dark-adapted pupil diameter" 30 : 639-644, 2004

19 Yuen NS, "Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy" 49 : 89-92, 2005

20 Yang HS, "Burst-shot infrared digital photography to determine scotopic pupil diameter" 32 : 2113-2117, 2006

21 Marx-Gross S, "Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels" 31 : 1372-1376, 2005

22 Derick RJ, "Brimonidine tartrate: a one-month dose response study" 104 : 131-136, 1997

23 deSousa JL, "Brimonidine for anisocoria" 114 : 1419-, 2007

24 Mastropasqua L, "Brimonidine and pupillary diameter" 105 : 1352-1353, 1998

25 Schuman JS, "A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group" 115 : 847-852, 1997

26 Duffin RM, "2.5% vs 10% phenylephrine in maintaining mydriasis during cataract surgery" 101 : 1903-1906, 1983